MedPath

Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients

Phase 4
Terminated
Conditions
Obesity
Arterial Hypertension
Hypercholesterolemia
Chronic Liver Disease
Acute Kidney Injury
Cardio Vascular Disease
Diabetes Mellitus
Registration Number
NCT02499185
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

To validate the use of \[TIMP-2\]●\[IGFBP-7\] to predict AKI in patients undergoing major intra abdominal surgery.

Detailed Description

A prospective pilot single center study to investigate the potential of \[TIMP-2\].\[IGFBP-7\] to predict AKI (Acute Kidney Injury) in patients undergoing major abdominal surgery. The investigators will measure the biomarker once preoperatively and 4-times postoperatively starting at arrival on PACU (post anesthesia care unit).The primary endpoint of this study is the development of AKI stage 2 or 3 within the first 72 postoperative hours.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
100
Inclusion Criteria
  • ≥ 18 years
  • High risk patients: General Surgery AKI Risk Index Class III, IV or V
  • Major abdominal surgery
Exclusion Criteria
  • Ongoing acute kidney injury Stage 2/3
  • History of kidney transplant

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Number of participants diagnosed with AKI stage 2 or 3 using the updated rifle "KDIGO" guidelines72 Hours
Secondary Outcome Measures
NameTimeMethod
Number of participants who need renal replacement therapy30 Days

the need renal replacement therapy wil be evaluated by the nephrologist (acid base disturbances, hypervolemia,...)

Trial Locations

Locations (1)

Universitair Ziekenhuis Brussel

🇧🇪

Jette, Brussels, Belgium

Universitair Ziekenhuis Brussel
🇧🇪Jette, Brussels, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.